Journey Medical Corporation Announces Closing of Initial Public Offering
16 nov. 2021 16h01 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Prices $35.2 Million Initial Public Offering
12 nov. 2021 07h00 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Announces Launch of its Initial Public Offering
08 nov. 2021 10h12 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization...
Journey Medical Corporation Enters $7.5 Million Line of Credit Agreement with East West Bank
05 avr. 2021 07h00 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz. and NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today...
Journey Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary of Eli Lilly and Company, to Acquire QBREXZA®
01 avr. 2021 07h00 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz. and NEW YORK, April 01, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today...
Journey Medical Corporation Recaps 2019 Growth
13 janv. 2020 07h30 HE
|
Journey Medical Corporation
Potent sales and marketing model drives continued commercial success of branded dermatology products Preliminary unaudited full-year 2019 net revenue expected to be between $33 million and $36...
Journey Medical Corporation Launches Targadox™ Oral Immediate-Release Tablet for Treatment of Severe Acne
17 oct. 2016 08h15 HE
|
Journey Medical Corporation
Targadox™ Is Journey’s Fourth Launched Product in the Past 12 Months Availability in Major U.S. Retail and Specialty Pharmacy Chains SCOTTSDALE, Ariz., Oct. 17, 2016 (GLOBE NEWSWIRE) -- ...
Journey Medical Corporation Launches Luxamend™ Wound Cream and Ceracade™ Skin Barrier Emulsion
25 juil. 2016 09h00 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., July 25, 2016 (GLOBE NEWSWIRE) -- Journey Medical Corporation, a subsidiary of Fortress Biotech, Inc. (NASDAQ:FBIO), launched the first two prescription products in its...